Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539861 · ClinicalTrials.gov registry record · NA
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
A NA study, sponsored by University of Michigan.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT03539861 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 2 participants.
The verdict
NCT03539861, a NA study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Hemodialysis is a therapy that filters waste, removes extra fluid and balances electrolytes. In hemodialysis, blood is removed from the body and filtered through a man-made membrane called a dialyzer, and then the filtered blood is returned to the body. Hemodialysis is associated with injury to the heart muscle called myocardial stunning. This may occur for many reasons, including removal of fluid during dialysis or low blood pressure. Initial ischemia and subsequent white blood cell infiltration into the injured myocardium play a critical role in the degree of myocardial ischemia reperfusion injury. In this study an additional man made membrane (selective cytopheretic device) and tubing will be added to the dialysis circuit. The device shifts the circulating white blood cells pool to a less inflammatory phenotype. Researchers believe the selective cytopheretic device will alter the phenotype of circulating white blood cells which play a role in myocardial stunning. The purpose of this study is to evaluate whether the selective cytopheretic device will reduce myocardial stunning events in hemodialysis patients. It will also report the rate of adverse events.
Interventions
- DEVICE Hemodialysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2021-08-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539861
The ClinicalTrials.gov registry entry for NCT03539861 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hemodialysis is the first listed.
NCT03539861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03539861 about?
NCT03539861 is a clinical study titled "Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients". Hemodialysis is a therapy that filters waste, removes extra fluid and balances electrolytes. In hemodialysis, blood is removed from the body and filtered through a man-made membrane called a dialyzer, and then the filtered blood is returned to the body. Hemodialysis is associated with injury to the ...
What is the current status of trial NCT03539861?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2019-09-24. Estimated completion is 2021-08-04.
What interventions are being tested in trial NCT03539861?
The interventions under investigation include: Hemodialysis (DEVICE).
Who is sponsoring clinical trial NCT03539861?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.